Linking Brain Imaging and Genomics in the Study of Alzheimer's Disease and Aging

Abstract:  My colleagues and I have been using positron emission tomography (PET) and magnetic resonance imaging (MRI) to detect and track the brain changes associated with Alzheimer's disease (AD) and normal brain aging in cognitively normal persons with two copies, one copy, and no copies of the apolipoprotein E (APOE) ɛ4 allele, a common AD susceptibility gene. In this review article, I consider how brain imaging techniques could be used to evaluate putative AD prevention therapies in cognitively normal APOE ɛ4 carriers and putative age‐modifying therapies in cognitively normal APOE ɛ4 noncarriers, how they could help investigate the individual and aggregate effects of putative AD risk modifiers, and how they could help guide the investigation of a molecular mechanism associated with AD vulnerability and normal neurological aging. I suggest how high‐resolution genome‐wide genetic and transcriptomic studies could further help in the scientific understanding of AD, aging, and other common and genetically complex phenotypes, such as variation in normal human memory performance, and in the discovery and evaluation of promising treatments for these phenotypes. Finally, I illustrate the push–pull relationship between brain imaging, genomics research, and other neuroscientific research in the study of AD and aging.

[1]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[2]  A D Roses,et al.  Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease) , 2007, The Pharmacogenomics Journal.

[3]  Satoshi Minoshima,et al.  Posterior cingulate cortex in Alzheimer's disease , 1994, The Lancet.

[4]  M. Viitanen,et al.  Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.

[5]  F. Gonzalez-Lima,et al.  Nonprogressive transgene-related callosal and hippocampal changes in PDAPP mice , 2006, Neuroreport.

[6]  G. Alexander,et al.  Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[8]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  J. Pritchard,et al.  Use of unlinked genetic markers to detect population stratification in association studies. , 1999, American journal of human genetics.

[10]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[11]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[12]  Jason J. Corneveaux,et al.  Common Kibra Alleles Are Associated with Human Memory Performance , 2006, Science.

[13]  Eric M Reiman,et al.  The Role of Biomarkers in Clinical Trials for Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[14]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[15]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[16]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[17]  Margaret A. Pericak-Vance,et al.  Hypothesis: Microtubule Instability and Paired Helical Filament Formation in the Alzheimer Disease Brain Are Related to Apolipoprotein E Genotype , 1994, Experimental Neurology.

[18]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[19]  G. Alexander,et al.  Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease , 1998, Neurology.

[20]  Lisa A. Weissfeld,et al.  Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.

[21]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[22]  Eric M. Reiman,et al.  Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice , 2006, Brain Research.

[23]  J. Ott,et al.  Trimming, weighting, and grouping SNPs in human case-control association studies. , 2001, Genome research.

[24]  Richard J. Caselli,et al.  Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease , 2001, Clinical Neuroscience Research.

[25]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[26]  J. Morris,et al.  Role of biomarkers in studies of presymptomatic Alzheimer’s disease , 2005, Alzheimer's & Dementia.

[27]  Z. Khachaturian.  Editorial: The five-five, ten-ten plan for Alzheimer's disease , 1992, Neurobiology of Aging.

[28]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[29]  Andreas Papassotiropoulos,et al.  A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. , 2005, The Journal of clinical psychiatry.

[30]  C. Jack,et al.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.

[31]  A D Roses,et al.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.

[32]  David W Craig,et al.  Applications of whole-genome high-density SNP genotyping , 2005, Expert review of molecular diagnostics.

[33]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[34]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[35]  E. Reiman,et al.  Alzheimer's disease a century later. , 2006, The Journal of clinical psychiatry.

[36]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[37]  Simon R. Cherry,et al.  Effects of Image Resolution on Autoradiographic Measurements of Posterior Cingulate Activity in PDAPP Mice: Implications for Functional Brain Imaging Studies of Transgenic Mouse Models of Alzheimer's Disease , 2002, NeuroImage.

[38]  G. Alexander,et al.  Positron Emission Tomography and Magnetic Resonance Imaging in the Study of Cognitively Normal Persons at Differential Genetic Risk for Alzheimer’s Dementia , 2004 .

[39]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[40]  Daniel Bandy,et al.  Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease , 1998, Annals of neurology.

[41]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[44]  Kevin M. Brown,et al.  Gene expression correlates of neurofibrillary tangles in Alzheimer's disease , 2006, Neurobiology of Aging.

[45]  Jonathan D. Smith,et al.  Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides , 1996, Nature Genetics.

[46]  Pietro Pietrini,et al.  Regional network of magnetic resonance imaging gray matter volume in healthy aging , 2006, Neuroreport.

[47]  F Gonzalez-Lima,et al.  Tracking Alzheimer's disease in transgenic mice using fluorodeoxyglucose autoradiography , 2000, Neuroreport.

[48]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[49]  Nils Homer,et al.  Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. , 2007, American journal of human genetics.

[50]  F. Gonzalez-Lima,et al.  Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease , 2001, Neuroreport.

[51]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[52]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[53]  Z. Khachaturian.  The five-five, ten-ten plan for Alzheimer's disease. , 1992, Neurobiology of aging.

[54]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[55]  A. Drzezga,et al.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  G. Alexander,et al.  Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism , 2005 .

[57]  W. Hsueh.  Genetic discoveries as the basis of personalized therapy: rosiglitazone treatment of Alzheimer's disease , 2006, The Pharmacogenomics Journal.

[58]  Margaret A. Pericak-Vance,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .

[59]  Brigitte Landeau,et al.  Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study , 2005, NeuroImage.

[60]  Eric M Reiman,et al.  Genetics, transcriptomics, and proteomics of Alzheimer's disease. , 2006, The Journal of clinical psychiatry.

[61]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[62]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[63]  Mayo Clinic,et al.  PRECLINICAL EVIDENCE OF ALZHEIMER’S DISEASE IN PERSONS HOMOZYGOUS FOR THE , 2000 .

[64]  G. Alexander,et al.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Yvette I. Sheline,et al.  Potential antecedent marker of Alzheimer disease , 2006 .

[66]  Nick C. Fox,et al.  An automated algorithm for the computation of brain volume change from sequential MRIs using an iterative principal component analysis and its evaluation for the assessment of whole-brain atrophy rates in patients with probable Alzheimer's disease , 2004, NeuroImage.

[67]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[68]  T Vogel,et al.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. , 1994, The American journal of pathology.

[69]  Nick C Fox,et al.  Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. , 2000, Archives of neurology.

[70]  Alan A. Wilson,et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.